|
|
From diabetes, chronic pancreatitis to pancreatic cancer: miRNA - a new marker of pancreatic cancer?
Škrha, Pavel ; Anděl, Michal (advisor) ; Bendlová, Běla (referee) ; Krechler, Tomáš (referee)
From diabetes, chronic pancreatitis to pancreatic cancer: miRNA - a new marker of pancreatic cancer? Pavel Škrha Abstract Introduction: Pancreatic cancer ranks among the cancers with the worst prognosis. High lethality of the disease is caused by late diagnose and a lack of powerful and early markers. The goal of this study was to observe the presence of early unspecific signs of the disease (new-onset diabetes mellitus and weight loss) and to test selected miRNAs as markers of pancreatic cancer, with subanalysis according to specific criteria (diabetes mellitus/prediabetes, its type, weight loss, cancer stage and size of the primary tumor, presence of chronic pancreatitis in cancer patients). Patients and methods: We have included 77 patients with ductal pancreatic adenocarcinoma, 26 with chronic pancreatitis, 39 patients with type 2 diabetes mellitus without any tumor disease and 25 control subjects. In the cancer group, there were 60 patients who also had diabetes/prediabetes and 18 with chronic pancreatitis in their personal history. Significant weight loss (> 5 % of body weight in 3 months or > 10 % of body weight in 6 months) was observed in 52 patients with the cancer. Relative expressions of miRNAs (miR-21, miR-30, miR-192, miR-196, miR-200, miR-423) were measured in the serum by real-time PCR...
|
|
|
From diabetes, chronic pancreatitis to pancreatic cancer: miRNA - a new marker of pancreatic cancer?
Škrha, Pavel ; Anděl, Michal (advisor) ; Bendlová, Běla (referee) ; Krechler, Tomáš (referee)
From diabetes, chronic pancreatitis to pancreatic cancer: miRNA - a new marker of pancreatic cancer? Pavel Škrha Abstract Introduction: Pancreatic cancer ranks among the cancers with the worst prognosis. High lethality of the disease is caused by late diagnose and a lack of powerful and early markers. The goal of this study was to observe the presence of early unspecific signs of the disease (new-onset diabetes mellitus and weight loss) and to test selected miRNAs as markers of pancreatic cancer, with subanalysis according to specific criteria (diabetes mellitus/prediabetes, its type, weight loss, cancer stage and size of the primary tumor, presence of chronic pancreatitis in cancer patients). Patients and methods: We have included 77 patients with ductal pancreatic adenocarcinoma, 26 with chronic pancreatitis, 39 patients with type 2 diabetes mellitus without any tumor disease and 25 control subjects. In the cancer group, there were 60 patients who also had diabetes/prediabetes and 18 with chronic pancreatitis in their personal history. Significant weight loss (> 5 % of body weight in 3 months or > 10 % of body weight in 6 months) was observed in 52 patients with the cancer. Relative expressions of miRNAs (miR-21, miR-30, miR-192, miR-196, miR-200, miR-423) were measured in the serum by real-time PCR...
|
|
| |
guest ::
